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Abstract: Molecular detection of the BCR-ABL1 fusion transcripts is necessary for the genetic
confirmation of a chronic myeloid leukemia diagnosis and for the risk classification of acute
lymphoblastic leukemia. BCR-ABL1 mRNAs are usually identified using a conventional RT-PCR
technique according to the BIOMED-1 method. In this study, we evaluated 122 BCR-ABL1-positive
samples with the Q-LAMP assay to establish if this technology may represent a valid alternative to the
qualitative BIOMED-1 PCR technique usually employed for the detection and the discrimination of the
common BCR-ABL1 transcripts (p190 and p210 isoforms). We found a 100% concordance rate between
the two methods. Specifically, the p190- and p210-positive samples were amplified by Q-LAMP with
a median threshold time (Tt) of 26.70 min (range: 24.45–31.80 min) and 20.26 min (range: 15.25-34.57
min), respectively. A median time of 19.63 was observed in samples displaying both (e13a2/e14a2)
p210 isoforms. Moreover, the Q-LAMP assay allowed recognition of the BCR-ABL1 e13a2 and e14a2
isoforms (median Tts 18.48 for e13a2 vs. 26.08 min for e14a2; p < 0.001). Finally, 20 samples harboring
rare BCR-ABL1 isoforms (e1a3, e13a3, e14a3, and e19a2) were correctly identified by the Q-LAMP
assay. We conclude that the Q-LAMP assay may represent a faster and valid alternative to the
qualitative BIOMED-1 RT-PCR for the diagnosis at BCR-ABL1-positive leukemias, especially when
samples are analyzed in centers with restricted resources and/or limited technical expertise.
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1. Introduction
The Philadelphia (Ph) chromosome is the first cytogenetic marker associated with a malignant
neoplasia as it is present in 95% of chronic myeloid leukemia (CML) cases, in 3-5% of pediatric acute
lymphoblastic leukemia (ALL), and in 15%–20% of adult ALL [1–3].
The Ph chromosome is generated by a reciprocal translocation between the long arms of
chromosomes 9 and 22 t(9;22) (q34;q11) with the ABL1 oncogene juxtaposed to the breakpoint
cluster region (BCR) gene on chromosome 22 [4]. This cytogenetic alteration gives rise to the BCR-ABL1
chimeric gene encoding for an oncoprotein with constitutive tyrosine kinase (TK) activity that alters
the proliferation rates, survival signaling, immunological interactions, and cytoskeleton dynamics of
hematopoietic stem cells [5–9]. The breakpoint in the BCR gene is most frequently located downstream
of exon 13 or exon 14 (e13 and e14, previously referred to as exons b2 and b3), in the major cluster
region (M-BCR), while the most common breakpoint in the ABL1 gene is upstream of exon 2 (a2). These
breakpoints lead to the e13a2 or e14a2 BCR-ABL1 rearrangements, which encode for a 210 kDa protein
called p210. In about 75% of BCR-ABL1-positive ALL, but <1% of CML patients, the breakpoint in
BCR occurs between exons 1 and 2 in the microcluster region (µ-BCR), generating the e1a2 mRNA
fusion that is translated into the p190 oncoprotein. In about 2–3% of CML patients, a breakpoint
downstream of BCR exon 19 results in an e19a2 fusion transcript that gives rise to a 230 kDa protein
(p230). Other infrequent breakpoints involve BCR exons 6 or 8 (e6a2 or e8a2) or ABL1 exon 3 (e13a3 or
e14a3) [1,10–14].
Several studies have investigated whether the quantity or quality of the transcript type may
influence the outcome of BCR-ABL1-positive patients [10,15–19]. Previous evidence has suggested
that the type of transcript may impact the response to tyrosine kinase inhibitors (TKIs) [3,20]. Indeed,
Jain et al. reported that CML patients with e13a2 display a trend towards inferior event-free (EFS)
and transformation-free survival (TFS) compared to the e14a2 isoform (alone or co-expressed with
e13a2) [10]. Moreover, in the imatinib (IM) era, some studies suggested that the e14a2 fusion was
associated with faster and deeper responses [15–17].
Currently, identification of BCR-ABL1 transcripts is routinely performed to confirm a CML or ALL
diagnosis and allow the timely assignment of an appropriate treatment regimen for each patient [21–24].
In the last 15 years, several qualitative and quantitative molecular techniques have been developed
to identify and measure BCR-ABL1 transcripts. With the introduction of real-time quantitative
polymerase chain reaction (RT-qPCR), serial measurements of BCR-ABL1 mRNA can be performed to
monitor patient outcomes and, if necessary, reassess the assigned therapy. The methodology used to
identify the BCR-ABL1 fusion has evolved over the years. The most common molecular diagnostic
method is based on a conventional RT-PCR following the BIOMED-1 protocol, a multistep procedure
that identifies the translocations and defines the breakpoints [25].
An easier and faster molecular assay for BCR-ABL1-positive leukemias may improve patient
management and should ideally be feasible in clinical laboratories located outside of a specialized
center, such as small hospitals or laboratories in developing countries.
The loop-mediated isothermal amplification (LAMP) technology is a non-PCR-based nucleic acid
amplification method that rapidly amplifies DNA or RNA targets under isothermal conditions. LAMP
is performed using a strand-displacement polymerase and does not require Taq DNA polymerase
or thermal cycling [26]. The potential diagnostic applications of this technology are remarkable and
rapidly expanding, particularly in the field of infectious [27–29] and hematologic diseases [30–32]. The
Q-LAMP assay (DiaSorin S.p.A., Saluggia, Italy) represents a technical improvement over the classical
LAMP resulting in a more sophisticated method suitable for the needs of oncohematology diagnoses.
In this study, we evaluate if the Q-LAMP technology may represent a valid alternative to the
BIOMED-1 PCR method for the detection and the discrimination of the common BCR-ABL1 transcripts
in Ph-positive leukemia patients. Moreover, we investigate if the Q-LAMP method is potentially able
to detect rare BCR-ABL1 isoforms.
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2. Results
2.1. Concordance between the Q-LAMP Assay and the Standard BIOMED-1 Method on p210 and p190
BCR-ABL1 Isoforms
In order to evaluate the Q-LAMP assay specificity we analyzed a total of 122 BCR-ABL1-positive
samples (102 positive for p210 and 30 for p190) and 50 negative samples (24 derived from
BCR-ABL1-negative patients and 26 from healthy human donors), as previously described by
Salmoiraghi et al. [33]. The obtained data were compared to results achieved with the RT-PCR
following the BIOMED-1 protocol. We found a 100% concordance rate between the two methods
(Table 1). Both p190- and p210-positive samples were identified by Q-LAMP in less than an hour
with visible amplification status at median Tt of 26.70 min (range: 24.45-31.80) and 20.26 min (range:
15.25–34.57), respectively (Figure 1A,B and Table 2). All negative samples were validated through
amplification of the housekeeping GUSß control gene with a median Tt of 41.94 min (range: 38.03–51.77)
(Figure 1C).
Table 1. Concordance between the Q-LAMP assay and the standard BIOMED-1 method on common
BCR-ABL1 isoforms.
Results by Conventional RT-PCR (BIOMED-1)
p190 p210 Negative Total
Q
-L
A
M
P
A
ss
ay
p190 14 / / 14
p210 / 108 / 107
Negative / / 50 50
Total 14 108 50 172
Table 2. Q-LAMP performance using common BCR-ABL1 isoforms.
Isoform
(N Sample) Mean Tt * (st. dev) Median Tt * (Range) CV
e1a2 27.03 26.70 0.07
(14) (1.87) (24.45–31.80) /
e13a2 18.64 18.48 0.08
(44) (1.41) (15.25–21.67) /
e14a2 25.46 26.08 0.13
(43) (3.29) (16.53–34.57) /
e13a2/e14a2 19.84 19.63 0.06
(21) (1.29) (17.93–23.20) /
* Threshold times (Tt) are reported in minutes; CV = coefficient of variation.
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Figure 1. BCR-ABL1 Q-LAMP amplification plot. Representative fluorescence quenching curves for 
BCR-ABL1 p190 (panel A, red curve) and for BCR-ABL1 e13a2 (panel B, gray curve), e14a2 (panel B, 
violet curve) or e13a2/e14a2 (panel B, green curve). In the negative specimen, there is amplification of 
the housekeeping control GUSß gene (panel C, pink curve). 
2.2. Q-LAMP Performance on Common BCR-ABL1 p210 Isoforms 
We next investigated a possible correlation between the Tt and the different transcript variants. 
We stratified patients according to their isoforms (e1a2, e13a2, e14a2, and both e13a2/e14a2) and then 
Figure 1. BCR-ABL1 Q-LAMP amplification plot. Representative fluorescence quenching curves for
BCR-ABL1 p190 (panel A, red curve) and for BCR-ABL1 e13a2 (panel B, gray curve), e14a2 (panel B,
violet curve) or e13a2/e14a2 (panel B, green curve). In the negative specimen, there is amplification of
the housekeeping control GUSß gene (panel C, pink curve).
Int. J. Mol. Sci. 2019, 20, 6106 5 of 12
2.2. Q-LAMP Performance on Common BCR-ABL1 p210 Isoforms
We next investigated a possible correlation between the Tt and the different transcript variants.
We stratified patients according to their isoforms (e1a2, e13a2, e14a2, and both e13a2/e14a2) and then
compared their Tts (Table 2). Interestingly, our statistical analysis demonstrated that the e13a2 and
e14a2 isoforms showed different Tts with a visible delay in the amplification of the longer isoform
(e14a2) (median Tt: 18.48 vs. 26.08 min, respectively; p < 0.001). A median time of 19.63 was observed in
samples expressing both p210 isoforms (e13a2/e14a2) (Table 2). This value was not significantly different
than the Tt observed in samples with e13a2 (p = 0.1332) (Figure 2A). On the contrary, a statistically
significant difference was detected between samples with both e13a2 and e14a2 and patients carrying
the e14a2 BCR-ABL1 transcript alone (p < 0.001) (Figure 2A). In order to verify if we could define a
cutoff in Tt minutes that would predict the expression of the common p210 variants, we performed a
ROC analysis, clustering e13a2 and e13a2/e14a2 patients as no differences in Tt were observed between
these groups. This analysis showed that a Tt higher than 21.55 min may be associated with a higher
probability of identifying e14a2-positive patients with a sensitivity of 88.37% and a specificity of 95.38%
(Figure 2B).
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Figure 2. Q-LAMP performance on common BCR-ABL1 p210 isoforms. (A) Median threshold times
(Tts) in minutes were determined for each group (e13a2, e13a2, and e13a2/e14a2 samples) and depicted
as boxplots delimited by the 25th (lower) and 75th (upper) percentile. Horizontal lines above and below
each boxplot indicate the 5th and 95th percentile, respectively. Thick lines in each boxplot represent
median Tts in each patients group. p values refer to statistical significance among the groups indicated
by the bracket. The distribution of the e14a2 Tt is significantly different compared to the e13a2 or the
e13a2/e14a2 groups (p < 0.001). (B) The ROC indicates the sensitivity, specificity, and cutoff value of the
different Tts.
2.3. Concordance between the Q-LAMP Assay and the Standard BIOMED-1 Method on Rare p210 and p190
BCR-ABL1 Isoforms
Approximately 5% of all CML or ALL patients are diagnosed with rare BCR-ABL1 rearrangements
that involve fusion of alternative exons, insertions, or breakpoints within exons such as e19a2 (the
most common rearrangement), e8a2, e13a3, e14a3, e1a3, and e6a2.
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In this study, we analyzed 20 patients with rare BCR-ABL1 isoforms (5 with e1a3, 9 with e13a3,
3 with e14a3 and 3 with e19a2) (Table 3). Although the Q-LAMP BCR-ABL qualitative assay is not
designed to detect or discriminate rare chromosomal rearrangements, the primer sets have been
improved to potentially amplify some of them. Interestingly, we obtained a 100% concordance rate
between standard RT-PCR and the Q-LAMP assay. The Tts observed were higher compared to the
common isoforms (Table 3), probably due to the longer transcripts deriving from the presence of
additional exons (Table 3).
Table 3. Concordance between the Q-LAMP assay and the reference BIOMED-1 method on rare p190
and p210 BCR-ABL1 isoforms.
Results by conventional RT-PCR (BIOMED-1)
e1a3 e13a3(b2a3)
e14a2
(b3a3) e19a2 Total
Q
-L
A
M
P
A
ss
ay
e1a3 5 / / / 5
e13a2 (b2a3) / 9 / / 9
e14a2 (b3a3) / / 3 / 3
e19a2 / / / 3 3
Total 5 9 3 3 20
3. Discussion
Q-LAMP is a qualitative assay for the detection and the discrimination of chromosomal
translocations performing simultaneous RNA reverse transcription and DNA amplification. Previously
published data generated from serial dilutions of RNA derived from ALL or CML cell lines (TOM-1 or
K-562) demonstrated that the Q-LAMP assay detected and discriminated the p190 (e1a2) and p210
(e13a2 and e14a2) BCR-ABL1 transcripts within 50 min. The assay amplifies these different targets,
including the endogenous internal control GUSβ gene [33], in a single tube and in a single step. The
authors also demonstrated that Q-LAMP showed 100% specificity on 70 replicates of wild type RNA
from 7 BCR-ABL1-negative cell lines [33].
In order to evaluate if this technology may represent a valid alternative to the qualitative
BIOMED-1 PCR for CML and ALL patients, we analyzed a total of 122 BCR-ABL1-positive and 50
negative samples using the Q-LAMP assay. In our analysis, the Q-LAMP showed complete concordance
with the BIOMED-1 PCR with a significantly lower time-to-results ratio, allowing the identification of
BCR-ABL1-positive patients in about 30 min (Table 2). Additionally, in the Table 4, we compared the
two techniques with emphasis on the advantages of each approach.
The molecular detection of BCR-ABL1 fusion transcripts is a necessary step for the diagnosis and
risk classification of CML and ALL [1,2]. In the current clinical setting, the introduction of multiple TKIs
has generated unprecedented rates of hematological, cytogenetic, and molecular responses, increasing
disease-free survival and overall survival [34,35]. Different studies reported that the e13a2 isoform is
associated with lower rates of complete cytogenetic response and major and deep molecular response
to different TKI [10,15,16,19]. Furthermore, recent studies have found that the e13a2 transcript has a
significant adverse impact on the maintenance of a treatment-free remission (TFR) after stopping TKI
therapy [36,37]. Therefore, it is essential to correctly identify the BCR-ABL1 isoforms expressed by
each patient. These molecular analyses should be performed by a specialized center that is routinely
monitored by a reference laboratory. In our study, we found that the Q-LAMP assay distinguished
the BCR-ABL1 e13a2 variant from the e14a2 isoform (median Tt 18.48 vs. 26.08 min, respectively;
p < 0.001). A recent study by Baccarani et al. reported that the percentage of patients co-expressing
both e13a2 and e14a2 isoforms ranges between 1.1% and 26.9% [38]. We found a statistically significant
difference between the Tt in samples co-expressing e13a2/e14a2 and those with the e14a2 isoform alone
(Figure 2). On the contrary, we observed only a 1 min Tt difference between specimens expressing
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e13a2 or co-expressing e13a2/e14a2. We assume that the observed Tt differences are influenced by the
amplification of different isoforms and that the e13a2 amplification may have an advantage compared
to e14a2, probably due to the shorter length of the former transcript. Therefore, when the Q-LAMP
assay shows an amplification range compatible with the e13a2 transcript or with the co-existence of
both e13a2/e14a2, a confirmatory RT-PCR may be warranted following the BIOMED-1 protocol [25].
Approximately 5% of Ph-positive patients are diagnosed with rare BCR-ABL1 rearrangement.
Although the purpose of the Q-LAMP assay is the detection and discrimination of the most common
BCR-ABL1 transcripts, the primer sets have been improved in order to potentially detect rare oncogenic
isoforms. In this study, we observed 100% concordance rates between the Q-LAMP and the standard
BIOMED-1 method when analyzing infrequent isoforms. We hypothesize that the observed delay in
term of Tt of these rare isoforms might be due to the presence of additional exons, which encode for
longer transcripts. Based on the results of our study, Q-LAMP might represent a valid option for the
reliable and rapid detection of rare BCR-ABL1 fusion. However, further studies on larger populations
should be performed in order to confirm our findings.
In conclusion, the Q-LAMP assay satisfies all the safety requirements of a validated diagnostic
test coupled with being a straightforward technical approach, thanks to the pre-assembled lyophilized
reagents and a one-step procedure that limits the risks of errors and optimizes laboratory workflow.
This closed-tube format could easily be adopted in non-highly specialized centers for an effective
diagnosis of Philadelphia-positive leukemias.
As an increasing number of manuscripts [10,15,16,19] suggest that in the future, the BCR-ABL1
variant may be included in the calculation of baseline risk scores, it is possible to envision a scenario in
which rapid and accurate determination of the BCR-ABL1 transcript will aid physicians in defining
which patients will achieve greater benefit from the different available TKIs.
Table 4. Comparison of the Q-LAMP assay and the BIOMED-1 method.
Q-LAMP Assay BIOMED-1 Method
Nucleic acid input (RNA
ng/sample) RNA (500) cDNA (1000)
Number of steps 1 ≥3
Reaction setup Easy Moderately complex (RT-PCR isrequired)
Detection of rare BCR-ABL1
isoforms Possible Possible
Time to results (minutes) <60 >300
Mark CE/IVD LDT
RT-PCR = reverse transcriptase PCR; LDT = laboratory developed test.
4. Materials and Methods
4.1. Patients
Bone marrow (BM) and peripheral blood (PB) samples were collected from 142 patients with
newly diagnosed chronic phase CML and Philadelphia-positive ALL. Patients were followed in four
Centers: Laboratorio di Medicina Interna ad Indirizzo Ematologico, Azienda Ospedaliera Universitaria
San Luigi Gonzaga (Turin); Laboratorio di Ematologia Oncologica, Ceinge-Biotecnologie Avanzate,
Università di Napoli “Federico II” (Naples); Centro di Oncologia ed Ematologia Sperimentale, Azienda
Ospedaliera Universitaria “Policlinico-Vittorio Emanuele” (Catania), and the Molecular Biology Unit,
University Hospital La Fe (Valencia).
The samples were collected from January 2016 to May 2019 and were retrospectively analyzed
based on the results previously obtained with the BIOMED-1 protocol [25]. The total analyzed RNA
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was derived from 14 samples with p190 (e1a2), 87 samples with the p210 transcript (44 samples with
e13a2 and 43 samples with e14a2), and 21 samples co-expressing both e13a2 and e14a2 (Supplementary
Table S1). Additionally, the analysis was performed on 20 samples derived from CML and ALL patients
with rare isoforms (5 with e1a3, 9 with e13a3, 3 with e14a3, and 3 with e19a2) (Supplementary Table
S1). Fifty negative samples were also included in the study, 24 from BCR-ABL1-negative patients and
26 from healthy donors.
Informed consent was obtained from each subject, and all procedures were performed in accordance
with the Helsinki Declaration and subsequent revisions.
4.2. RNA Extraction
Total RNA was extracted from PB or BM polymorphonuclear cells collected in EDTA or sodium
citrate, using different methods: phenol–chloroform (N = 7), RNeasy Mini Kit, QIAGEN (N = 50),
QIAsymphony, QIAGEN (N = 72), and Maxwell 16 LEV simplyRNA Kit, Promega (N = 63), according
to the respective manufacturers’ instructions.
Purified total RNA was quantified with a spectrophotometer (NanoDrop, Technologies Inc.) at
wavelengths of 230, 260, and 280 nm. RNA integrity was then verified by running samples on 1.2%
denaturing agarose gels. Total RNA samples were stored at −20 or −80 ◦C until their use.
4.3. BCR-ABL1 Q-LAMP Assay
The Q-LAMP is a qualitative assay for the detection and the discrimination of chromosomal
translocations directly from total RNA samples. The original LAMP method has been modified
introducing a polymerase with simultaneous RNA reverse transcription and DNA amplification
activity. The implementation of fluorescent dyes allowed to perform multiplex reaction analyses
by using specific primer sets. The assay includes an endogenous housekeeping gene (GUSß) that is
amplified as an internal control in the same tube of the target reaction to check for the real absence
of the translocation or for artifacts such as RNA degradation, reaction inhibition, or technical failure.
The fluorescent signals can be monitored in real time onto the dedicated instrument LIAISON® IAM
(DiaSorin S.p.A., Saluggia, Italy) that provides results within 60 min. At time zero, the reaction
excited with appropriate wavelength UV light emits maximum fluorescence. As a consequence of the
amplification, fluorescence decreases exponentially thanks to the natural quenching effect of newly
synthetized amplicons (Figure 3A).
The Iam BCR-ABL qualitative assay is a triplex fluorescent Q-LAMP assay designed for the
differential detection and discrimination of BCR-ABL1 p190 (e1a2) and p210 (e13a2, e14a2) fusion
transcripts in a single one-step reaction with pre-assembled lyophilized reagents (Figure 3B).
A total of 500 ng of RNA was used for each sample in a final reaction volume of 25 µL. The assay
was performed following the manufacturer’s instructions (DiaSorin S.p.A., Saluggia, Italy) and each
analytical session included a p190/p210 double-positive control, a negative control (positive for the
housekeeping GUSß gene), and a no template control (nuclease-free water). During the amplification,
BCR-ABL1 samples positive for p190 generate a signal in the 500 nm channel, while samples positive
for p210 generate a signal in the 570 nm channel. All BCR-ABL1-negative samples were confirmed from
the amplification of the GUSß control gene that produces a signal in the 530 nm channel (Figure 3C).
The housekeeping GUSß gene was not amplified in BCR-ABL1 p190 (e1a2) or p210 (e13a2, e14a2)
samples, due to the preferential amplification of the oncogenic isoforms. On the contrary, samples
harboring the rare BCR-ABL1 p190 (e1a3) or p210 (e13a3, e14a3 and e19a2) isoforms were amplified at
a later time, with a positive signal for the GUSß control gene.
All results were expressed as threshold time (Tt) in minutes, defined as the minute at which the
sample fluorescence reaches 50% of quenching [30].
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detects and discriminates the BCR-ABL1 p190 (e1a2) and p210 (e13a2, e14a2) transcripts. (C) BCR-ABL1
p190-positive samples generate a signal in the 500 nm channel, while samples positive for p210 generate
a signal in the 570 nm c annel. The amplification of the GUSß control gene produces a ignal in the
530 nm c annel.
4.4. Statistical Analyses
Threshold times of the three different p210 isoform groups (e13a2, e14a2 and e13a2/e14a2) were
compared using the Kruskal–Wallis test followed by Dunnett’s multiple comparisons. The variance of
the groups was calculated with the Bartlett test and the data distribution with the Kolmogorov–Smirnov
test. The receiver operating characteristic (ROC) approach was applied to identify a possible cutoff in
terms of Tt between carriers of different isoforms of the p210 fusion gene. Sensitivity and specificity
were calculated, and the curve and the area under the curve (AUC) were defined. All analyses were
Int. J. Mol. Sci. 2019, 20, 6106 10 of 12
performed using GraphPad Prism version 8.1.1 for Windows (GraphPad Software, La Jolla California
USA, www.graphpad.com).
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/24/
6106/s1.
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